Abstract

Loring and Goldstein presented a case of a woman with Multiple Sclerosis (MS) who failed the traditional performance validity criteria of the WMT. Scoring lower than the mean from patients with Alzheimer’s Disease on extremely easy subtests, the patient carried on to produce a WMT profile which is typical of someone with invalid test results, based on the usual interpretation, which is standardized within the Advanced Interpretation Program. Statements were made that are incorrect, including the claim there are no available data on the WMT in MS patients, that the minor tranquilizer Lorazepam can explain WMT failure even in healthy adults and that this patient produced a neuropsychological profile that is credible and typical of MS. We report data from MS patients given comprehensive neuropsychological assessment, including the WMT. Loring and Goldstein’s interpretation of this case does not fit the facts.

摘要

Loring 和 Goldstein 介绍了一名多发性硬化症 (MS) 女性的案例，她未能通过 WMT 的传统绩效有效性标准。在极其简单的子测试中得分低于阿尔茨海默病患者的平均值，该患者继续生成 WMT 配置文件，该配置文件基于高级解释程序中标准化的通常解释，这是具有无效测试结果的人的典型特征。做出的陈述不正确，包括声称没有关于 MS 患者 WMT 的可用数据、次要镇静剂劳拉西泮即使在健康成人中也可以解释 WMT 失败以及该患者产生的神经心理学特征是可信的和典型的 MS . 我们报告了来自 MS 患者的数据，这些患者进行了全面的神经心理学评估，包括 WMT。